Percheron Therapeutics logo

Percheron Therapeutics(OTC) ATHJF

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-95%
5 Year-98%
1 Year-40%
1 Month-15%
N/A
Percheron Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-27
Percheron Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-15.04%USD 0.002026-06-25
1 month-15.04%USD 0.002026-06-25
3 month-52%USD 0.012025-12-22
Year to date-52%USD 0.012025-12-22
1 year-40%USD 0.002025-03-31
3 year-95.2%USD 0.052023-07-05
5 year-98.4%USD 0.152021-07-22
Since inception-95.2%USD 0.052007-10-22

Percheron Therapeutics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$4.55M

Net Income (TTM)

-A$23.30M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 29, 2024

ATHJF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Percheron Therapeutics

Antisense Therapeutics Limited is an Australian biotechnology company focused on developing innovative antisense pharmaceuticals. The company has a promising pipeline that includes two primary drug candidates aimed at treating various inflammatory conditions and diseases linked to excessive growth hormone activity.

Products and Services
  • ATL1102: An antisense inhibitor targeting CD49d, in Phase II trials
  • ATL1103: A second-generation antisense medication, completed Phase II trials
  • Research and development of antisense pharmaceuticals for various conditions
Growth Outlook
  • Strong pipeline with two drug candidates in advanced clinical stages
  • Potential market expansion in inflammatory and growth-related diseases
  • Increased focus on research and development to drive future growth
Financial Highlights
  • Recent quarterly revenue of 1,768,070 AUD, showing growth from previous quarters
  • Cash and cash equivalents of 11,866,659 AUD as of June 30, 2024
  • Operating expenses primarily driven by research and development investments
Antisense Therapeutics Limited operates in the healthcare sector, specifically within drug manufacturing, and has established itself as a key player in the biotechnology field. The company’s focus on antisense technology positions it well to address unmet medical needs in various therapeutic areas. The ongoing clinical trials for ATL1102 and ATL1103 highlight the company's commitment to advancing its innovative treatments, which could lead to significant market opportunities. The financial data indicates a solid cash position, which is crucial for funding ongoing research and development efforts. The recent revenue growth reflects the company's potential to capitalize on its drug candidates as they progress through clinical trials. Overall, Antisense Therapeutics Limited presents an intriguing opportunity for investors interested in the biotechnology sector, particularly in companies focused on innovative therapeutic solutions.
AI Generated • Sep 17, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

4

CEO

James Stuart Garner, PhD, MBA

Website

www.PercheronTx.com

Headquarters

Toorak, VIC 3142, AU

ATHJF Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

N/A

Return on Capital

-125.84%

Return on Assets

N/A

Earnings Yield

N/A

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

A$4.45M

Operating Income

-A$23.65M

EBITDA

-A$23.27M

Operating Cash Flow

-A$18.36M

Capital Expenditure

-A$32.90K

Free Cash Flow

-A$18.39M

Cash & ST Invst.

A$11.87M

Total Debt

A$39.87K

Percheron Therapeutics Performance Analysis

Percheron Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
20262026-06-30AUD 0N/A
Percheron Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22022-12-30-67.5%
Q42023-06-30120.2%
Q22023-12-3010.5%
Q42024-06-3047.3%
Percheron Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.0170.8%
20242024-06-30AUD -0.01-22.5%
20252025-06-30AUD -0.017.0%
20262026-06-30AUD -0.00-69.6%
Percheron Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22022-12-30-85.7%
Q42023-06-30-17.9%
Q22023-12-3028.3%
Q42024-06-30-6.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2024YOY CHG

Revenue

A$1.77M

+16.5%

Gross Profit

A$1.75M

+17.0%

Gross Margin

98.92%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

-A$7.18M

-153.6%

EBITDA

-A$7.17M

-151.1%

Quarterly Fundamentals

Name
Q4 2024YOY CHG

Total Cash

A$11.87M

-38.3%

Total Debt

A$39.87K

-82.5%

Accounts Receivable

A$2.51M

+36.3%

Inventory

A$0.00

-100.0%

Long Term Debt

A$0.00

-100.0%

Short Term Debt

A$39.87K

-57.6%

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-A$5.37M

-27.1%

Operating Cash Flow

-A$5.37M

-27.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OCELOrganicell Regenerative Medicine, Inc.
$2.74-0.27%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$107.08-5.34%
NVDANvidia
$230.48-2.94%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$33.79+10.24%
BITOProShares Trust - ProShares Bitcoin ETF
$10.93-1.88%

Questions About ATHJF

What is the current price of Percheron Therapeutics?

Percheron Therapeutics is trading at N/A per share.

What is the 52-week range for Percheron Therapeutics?

Over the past 52 weeks, Percheron Therapeutics has traded between N/A and N/A.

How much debt does Percheron Therapeutics have?

As of the most recent reporting period, Percheron Therapeutics reported total debt of A$19.25K.

How much cash does Percheron Therapeutics have on hand?

Percheron Therapeutics reported A$1.77M in cash and cash equivalents in its most recent financial results.

What is Percheron Therapeutics’s dividend yield?

Percheron Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services